1 day Ago By Defense World Staff
Federated Hermes Inc. boosted its holdings in Blueprint Medicines Co. ( NASDAQ:BPMC – Free Report ) by 27.
8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,354 shares of the biotechnology company’s stock after buying an additional 13,579 shares during the quarter. Federated Hermes Inc.
owned approximately 0.10% of Blueprint Medicines worth $6,721,000 at the end of the most recent reporting period. Other large investors have also added to or reduced their stakes in the company.
Principal Financial Group Inc. raised its holdings in Blueprint Medicines by 331.9% in the 1st quarter.
Principal Financial Group Inc. now owns 62,670 shares of the biotechnology company’s stock valued at $5,945,000 after buying an additional 48,160 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Blueprint Medicines during the 1st quarter valued at approximately $474,000.
Vanguard Group Inc. increased its position in Blueprint Medicines by 2.5% during the 4th quarter.
Vanguard Group Inc. now owns 6,114,970 shares of the biotechnology company’s stock valued at $564,045,000 after purchasing an additional 147,827 shares during the period. Comerica Bank increased its position in Blueprint Medicines by 2,582.
9% during the 1st quarter. Comerica Bank now owns 10,839 shares of the biotechnology company’s stock valued at $1,028,000 after purchasing an additional 10,435 shares during the period. Finally, Axiom Investors LLC DE acquired a new stake in Blueprint Medicines during the 4th quarter valued at approximately $2,212,000.
Analyst Upgrades and Downgrades BPMC has been the subject of a number of recent analyst reports. Robert W. Baird increased their target price on shares of Blueprint Medicines from $112.
00 to $127.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Oppenheimer increased their target price on shares of Blueprint Medicines from $114.
00 to $125.00 and gave the company an “outperform” rating in a research report on Monday, July 8th. Guggenheim raised their price objective on shares of Blueprint Medicines from $130.
00 to $138.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Morgan Stanley raised their price objective on shares of Blueprint Medicines from $110.
00 to $115.00 and gave the stock an “equal weight” rating in a research report on Friday, July 12th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $125.
00 price objective on shares of Blueprint Medicines in a research report on Friday, June 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $120.
00. Insider Buying and Selling at Blueprint Medicines In other news, insider Debra Durso-Bumpus sold 8,817 shares of the business’s stock in a transaction dated Wednesday, July 3rd. The stock was sold at an average price of $111.
29, for a total transaction of $981,243.93. Following the completion of the transaction, the insider now owns 43,763 shares of the company’s stock, valued at $4,870,384.
27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website . In related news, insider Debra Durso-Bumpus sold 8,817 shares of the business’s stock in a transaction that occurred on Wednesday, July 3rd.
The stock was sold at an average price of $111.29, for a total value of $981,243.93.
Following the completion of the sale, the insider now owns 43,763 shares in the company, valued at approximately $4,870,384.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link .
Also, insider Philina Lee sold 41,913 shares of the business’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $93.19, for a total value of $3,905,872.
47. Following the completion of the sale, the insider now owns 34,729 shares of the company’s stock, valued at approximately $3,236,395.51.
The disclosure for this sale can be found here . Insiders sold 128,947 shares of company stock valued at $13,065,852 in the last quarter. 4.
21% of the stock is currently owned by corporate insiders. Blueprint Medicines Trading Up 0.2 % NASDAQ BPMC opened at $86.
51 on Wednesday. Blueprint Medicines Co. has a one year low of $43.
89 and a one year high of $121.90. The business’s fifty day moving average is $99.
93 and its 200-day moving average is $99.14. The stock has a market capitalization of $5.
42 billion, a price-to-earnings ratio of -17.99 and a beta of 0.58.
The company has a debt-to-equity ratio of 1.06, a current ratio of 3.71 and a quick ratio of 3.
65. Blueprint Medicines ( NASDAQ:BPMC – Get Free Report ) last announced its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($0.
80) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.29) by $0.49.
The business had revenue of $138.20 million for the quarter, compared to analysts’ expectations of $104.02 million.
Blueprint Medicines had a negative return on equity of 157.30% and a negative net margin of 56.64%.
The firm’s quarterly revenue was up 139.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($2.
19) EPS. Equities research analysts predict that Blueprint Medicines Co. will post -3.
99 EPS for the current year. Blueprint Medicines Company Profile ( Free Report ) Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.
Read More Five stocks we like better than Blueprint Medicines Stock Sentiment Analysis: How it Works Galmed Pharmaceuticals Surges 400%: What’s Behind the Explosion? Most active stocks: Dollar volume vs share volume Gold Hits New All-Time Highs: 3 Stocks to Ride the Surge Comparing and Trading High PE Ratio Stocks Intel: Why It’s Time to Reconsider This Beaten-Down Chipmaker Want to see what other hedge funds are holding BPMC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Blueprint Medicines Co. ( NASDAQ:BPMC – Free Report ).
Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter ..
